CXCR3, a double-edged sword in tumor progression and angiogenesis

C Billottet, C Quemener, A Bikfalvi - … et Biophysica Acta (BBA)-Reviews on …, 2013 - Elsevier
C Billottet, C Quemener, A Bikfalvi
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2013Elsevier
CXC chemokines are involved in chemotaxis, regulation of cell growth, induction of
apoptosis and modulation of angiostatic effects. CXCL9, CXCL10, CXCL11, CXCL4 and its
variant CXCL4L1 are members of the CXC chemokine family, which bind to the CXCR3
receptor to exert their biological effects. These chemokines are associated with a variety of
human diseases including chronic inflammation, immune dysfunction, cancer and
metastasis. In this review, we focus on accumulating evidence demonstrating the pivotal role …
Abstract
CXC chemokines are involved in chemotaxis, regulation of cell growth, induction of apoptosis and modulation of angiostatic effects. CXCL9, CXCL10, CXCL11, CXCL4 and its variant CXCL4L1 are members of the CXC chemokine family, which bind to the CXCR3 receptor to exert their biological effects. These chemokines are associated with a variety of human diseases including chronic inflammation, immune dysfunction, cancer and metastasis. In this review, we focus on accumulating evidence demonstrating the pivotal role of CXCR3 in tumor progression. Its effects are mediated directly in tumor cells or indirectly through the regulation of angiogenesis and tumor immunity. Understanding the emerging role of CXCR3 and its signaling mechanisms further validates this receptor as a biomarker and therapeutic target for tumor progression and tumor angiogenesis.
Elsevier